← Patent-cliff monitor small molecule ZILBRYSQ ZILUCOPLAN SODIUM
Loss of exclusivity June 2035 latest FDA-listed patent expiry
Company UCB → See this company's full patent-cliff portfolio Drug detail Brand name ZILBRYSQ Active ingredient ZILUCOPLAN SODIUM Strength EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval October 2023 Marketing status RX
Listed patents Patent Expires Type 11752190 June 2035 product 11014965 June 2035 substance 10435438 June 2035 substance 10208089 June 2035 substance 10106579 June 2035 substance, product 10835574 June 2035 product 11535650 June 2035 product 10562934 June 2035 substance 11965040 June 2035 product
Regulatory exclusivity Code Expires ODE-446 October 2030 NCE October 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.